Adverse effects followed by immunization with COVISHIELD and COVAXIN among health care personnel in a tertiary care hospital of India

Narendar Koyagura; Prashanth Kumar Patnaik; Jaya Prakash Konda; Prasanna Vedula; Ksheerasagar Vinay Kumar; Goparaju Anumolu

doi:10.53730/ijhs.v6nS4.7926

Authors

Narendar Koyagura Associate Professor, Department of Pharmacology, RVM Institute of Medical Sciences & Research Center, Siddipet- 502279, Telangana, India
Prashanth Kumar Patnaik
prashanthpaul86@gmail.com
Assistant Professor, Department of Pharmacology, RVM Institute of Medical Sciences & Research Center, Siddipet- 502279, Telangana, India
Jaya Prakash Konda Assistant Professor, Department of Pharmacology, RVM Institute of Medical Sciences & Research Center, Siddipet- 502279, Telangana, India
Prasanna Vedula Professor & Head, Department of Pharmacology, RVM Institute of Medical Sciences & Research Center, Siddipet- 502279, Telangana, India
Ksheerasagar Vinay Kumar Assistant Professor, Department of Pharmacology, RVM Institute of Medical Sciences & Research Center, Siddipet- 502279, Telangana, India
Goparaju Anumolu Assistant Professor, Department of Community Medicine, RVM Institute of Medical Sciences & Research Center, Siddipet- 502279, Telangana, India

Keywords:

COVID-19 vaccine, covishield, covaxin, post vaccination effect

Abstract

The ongoing Corona Virus Disease (COVID-19) is a pandemic disease adversely affecting health and also incurred severe financial losses globally. Vaccination is the important preventing measure to combat COVID-19 infection. Vaccine hesitancy due to the fear of side effects is a major drawback for successful implementation of immunization programs. Extensive studies on safety of COVID-19 vaccination are much needed to address this problem. The current study aims at evaluating adverse effects following vaccination against COVID-19 infection. A total of 584 healthcare personnel who received either COVISHIELD or COVAXIN were included in the study. The adverse effects after first and second dose of vaccines in different time intervals (<24hrs, 24-48hrs, 3-7days) were recorded by using World Health Organization (WHO) based questionnaire. Among the participants, 360 received COVISHIELD and 220 received COVAXIN vaccine. Majority of the subjects experienced side effects within first 24hrs of first dose (COVISHIELD 84%, COVAXIN 90%) and also of second dose (COVISHIELD 73%, COVAXIN 89%). Side effects like general weakness, headache, fever, chills and myalgia were the most common side effects observed with both vaccines.

Downloads

Download data is not yet available.

References

Darbar S, Agarwal S, Saha S. (2021). COVID19 Vaccine: COVAXIN-India’s First Indigenous Effective Weapon to Fight against Coronavirus (A Review). Parana Journal of Sciences Education, 7(3), 1-9. http://tiny.cc/PJSE24476153v7i3p001-009

Das L, Meghana A, Paul P, Ghosh S. (2021). Are We Ready For Covid–19 Vaccines?–A General Side Effects Overview. Current Medical Research Opinion, 4(02), 830-841. https://doi.org/10.15520/jcmro.v4i02.398

DeRoo SS, Pudalov NJ, Fu LY. (2020). Planning for a COVID-19 vaccination program. Jama, 323(24), 2458-2459. https://doi.org/10.1001/jama.2020.8711

Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. (2021). COVID-19 vaccine challenges: What have we learned so far and what remains to be done?. Health Policy, 125(5), 553-567. https://doi.org/10.1016/j.healthpol.2021.03.013

Hu B, Guo H, Zhou P, Shi ZL. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 19(1), 141-154. https://doi.org/10.1038/s41579-020-00459-7

Ita K. (2021). Coronavirus disease (COVID-19): Current status and prospects for drug and vaccine development. Archives of Medical Research, 52(1), 15-24. https://doi.org/10.1016/j.arcmed.2020.09.010

Jaiswal KM, Dudhgaonkar S, Raghute L, Uike P, Kohli S, Anand I. (2021). An assessment of AEFI COVID-19 vaccination in health care workers at a tertiary health care centre in central India. Microbiology Research International, 9(2), 46-50. https://doi.org/10.30918/MRI.92.21.017

Kaur SP, Gupta V. (2020). COVID-19 Vaccine: A comprehensive status report. Virus Research, 288(1), 1-12. https://doi.org/10.1016/j.virusres.2020.198114

Kaur U, Ojha B, Pathak BK, Singh A, Giri KR, Singh A, et al. (2021). A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers-first results from India. E Clinical Medicine, 38(1), 1-11. https://doi.org/10.1016/j.eclinm.2021.101038

Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. (2021). Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. NPJ Vaccines, 6(1), 1-7. https://doi.org/10.1038/s41541-021-00327-2

Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine, 27(2), 225-8. https://doi.org/10.1038/s41591-020-1124-9

Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, et al. (2021). Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. Journal of Korean Medical Science, 36(21), 1-12. https://doi.org/10.3346/jkms.2021.36.e153

Luyten J, Bruyneel L, Van Hoek AJ. (2019). Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument. Vaccine, 37(18), 2494-2501. https://doi.org/10.1016/j.vaccine.2019.03.041

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939-949. https://doi.org/10.1016/S1473-3099(21)00224-3

Mohakuda SS, Nigam A, Rajesh K, Sashindran VK, Sharma H, Singh B, et al. (2021). Covishield India: Demystifying Myths Through an Early Multicenter Safety Study. American Journal of Managed Care, 27(10), 1-10. https://doi.org/10.37765/ajmc.2021.88694

Ozdemir, L, Pnarc, E, Akay B N, Akyol A. (2013). Effect of Methylprednisolone Injection Speed on the Perception of Intramuscular Injection Pain. Pain Management Nursing, 14(1), 3–10. https://doi.org/10.1016/j.pmn.2010.03.002

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. The New England Journal of Medicine, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577

Sallam M. (2021). COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines, 9(2), 160. https://doi.org/10.3390/vaccines9020160.

Seth PK. (2021). A Brief Report of the NASI Webinar on Building Confidence on COVID Vaccines. National Academy Science Letters, 44(4), 373-376. https://doi.org/10.1007/s40009-021-01058-7

Shrestha S, Devbhandari RP, Shrestha A, Aryal S, Rajbhandari P, Shakya B, et al. (2021). Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal. Journal of Patan Academy Health Sciences, 8(1), 9-17. https://doi.org/10.3126/jpahs.v8i1.36242

Singh JA, Upshur RE. (2021). The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. The Lancet Infectious Diseases, 21(4), e103-109. https://doi.org/10.1016/S1473-3099(20)30923-3.

World Health Organization - Global Manual on Surveillance of Adverse Events Following Immunization. Available at: https://www.who.int/vaccine_safety/publications/Global_Manual_on_Surveillance_of_AEFI.pdf. Accessed: 10 January 2021.

Yan Y, Shin WI, Pang YX, Meng Y, Lai J, You C, et al. (2020). The first 75 days of novel Coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and treatment. International Journal of Environmental Research and Public Health, 17(7), 1-23. https://doi.org/10.3390/ijerph17072323.

Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label. Lancet, 395(10240), 1845-1854. https://doi.org/10.1016/S0140-6736(20)31208-3